XNK Therapeutics AB, a Sweden-based clinical stage immunotherapy company that is focused on bringing new and more effective treatments to cancer patients, announced on Monday that Johan Liwing, CEO, will make a presentation at the DNB Nordic Healthcare Conference in Oslo, Norway, on 14 December at 10:15am CET.
This presentation will be followed by a short Q&A session, moderated by a DNB analyst.
The company is developing autologous NK cell-based cell therapy with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumour indications. Its most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member